Goto 1996a.

Methods	4‐week washout period 12‐week before‐and‐after study
Participants	163 men and women with type IIa and IIb hyperlipidaemia aged 20‐70 years old were randomised to receive cerivastatin 162 men and women with type IIa and IIb hyperlipidaemia aged 20‐70 years old were randomised to receive pravastatin TC ≥ 220 mg/dL (5.69 mmol/L), moderate hypertension, mild diabetes, obese, cholelithiasis Exclusion criteria: secondary hyperlipidaemia, hypothyroidism, Cushings syndrome, obstructive gallbladder disease, SLE, uncontrolled diabetes, severe hypertension, alcoholism, various hormonal agents, drugs that interfere with lipid metabolism, severe brain disease, liver and kidney dysfunction, diet therapy for obesity, pancreatic disease, cerebrovascular disease, MI within 3 months of trial, drug hypersensitivity, potential for pregnancy and lactation Cerivastatin 0.15 mg/d baseline TC: 7.12 mmol/L (275 mg/dL) Cerivastatin 0.15 mg/d baseline LDL‐C: 4.98 mmol/L (193 mg/dL)
Interventions	Cerivastatin 0.15 mg/d evening dosing Pravastatin 10 mg/d
Outcomes	Percentage change from baseline at 8 weeks of blood TC and LDL‐C
Source of funding	Unknown
Notes	Pravastatin 10 mg/d was not analysed HDL‐C and TG data were excluded because the given data and the calculated values differed by > 10%
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before‐and‐after design
Allocation concealment (selection bias)	High risk	Controlled before‐and‐after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐C	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAE	High risk	No comparison possible
Incomplete outcome data (attrition bias) Total cholesterol	High risk	[(163‐137)/163]*100 = 16.0% participants were not included in the efficacy analysis
Incomplete outcome data (attrition bias) LDL cholesterol	High risk	[(163‐130)/163]*100 = 20.2% participants were not included in the efficacy analysis
Incomplete outcome data (attrition bias) HDL cholesterol	High risk	Excluded because the given data and the calculated values differed by > 10%
Incomplete outcome data (attrition bias) Triglycerides	High risk	Excluded because the given data and the calculated values differed by > 10%
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding not reported